Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD
Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD
复制标题
DOI：
10.1111/eci.12486
复制
发表时间：
2015-09
影响因子：
5.5
通讯作者：
A. Pathil;G. Liebisch;J. Okun;W. Chamulitrat;G. Schmitz;W. Stremmel
中科院分区：
文献类型：
--
作者：
A. Pathil;G. Liebisch;J. Okun;W. Chamulitrat;G. Schmitz;W. Stremmel
肝脏脂肪堆积伴脂质平衡紊乱是非酒精性脂肪性肝病（NAFLD）的标志。胆汁酸磷脂缀合物熊脱氧胆酰溶血磷脂酰乙醇酰胺（UDCA - LPE）是一种新型抗炎剂，对小鼠高脂肪饮食（HFD）诱导的NAFLD具有肝脏保护作用。这项工作的目的是研究UDCA - LPE引起的肝脂质组的变化。
Hepatic fat accumulation with disturbed lipid homoeostasis is a hallmark of nonalcoholic fatty liver disease (NAFLD). The bile acid phospholipid conjugate Ursodeoxycholyl lysophosphatidylethanolamide (UDCA‐LPE) is a novel anti‐inflammatory agent with hepatoprotective effects in murine high‐fat‐diet (HFD)‐induced NAFLD. The aim of this work was to study changes in the hepatic lipidome due to UDCA‐LPE.